The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition123

Background: Higher coffee intake has been purportedly related to a lower risk of liver cancer. However, it remains unclear whether this association may be accounted for by specific biological mechanisms. Objective: We aimed to evaluate the potential mediating roles of inflammatory, metabolic, liver injury, and iron metabolism biomarkers on the association between coffee intake and the primary form of liver cancer—hepatocellular carcinoma (HCC). Design: We conducted a prospective nested case-control study within the European Prospective Investigation into Cancer and Nutrition among 125 incident HCC cases matched to 250 controls using an incidence-density sampling procedure. The association of coffee intake with HCC risk was evaluated by using multivariable-adjusted conditional logistic regression that accounted for smoking, alcohol consumption, hepatitis infection, and other established liver cancer risk factors. The mediating effects of 21 biomarkers were evaluated on the basis of percentage changes and associated 95% CIs in the estimated regression coefficients of models with and without adjustment for biomarkers individually and in combination. Results: The multivariable-adjusted RR of having ≥4 cups (600 mL) coffee/d compared with <2 cups (300 mL)/d was 0.25 (95% CI: 0.11, 0.62; P-trend = 0.006). A statistically significant attenuation of the association between coffee intake and HCC risk and thereby suspected mediation was confirmed for the inflammatory biomarker IL-6 and for the biomarkers of hepatocellular injury glutamate dehydrogenase, alanine aminotransferase, aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), and total bilirubin, which—in combination—attenuated the regression coefficients by 72% (95% CI: 7%, 239%). Of the investigated biomarkers, IL-6, AST, and GGT produced the highest change in the regression coefficients: 40%, 56%, and 60%, respectively. Conclusion: These data suggest that the inverse association of coffee intake with HCC risk was partly accounted for by biomarkers of inflammation and hepatocellular injury.

[1]  Matthew S. Fritz,et al.  Mediation analysis. , 2019, Annual review of psychology.

[2]  E. Riboli,et al.  Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: Multicentre, prospective cohort study , 2015, International journal of cancer.

[3]  R. Sinha,et al.  Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999‐2010 , 2014, Hepatology.

[4]  Xifeng Wu,et al.  High serum iron is associated with increased cancer risk. , 2014, Cancer research.

[5]  B. Neuschwander‐Tetri,et al.  Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[6]  T. Mizoue,et al.  Coffee Intake is Associated With Lower Levels of Oxidative DNA Damage and Decreasing Body Iron Storage in Healthy Women , 2014, Nutrition and cancer.

[7]  U. Nöthlings,et al.  Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer , 2014, Hepatology.

[8]  M. Lean,et al.  Coffee: biochemistry and potential impact on health. , 2014, Food & function.

[9]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[10]  S. Saab,et al.  Impact of coffee on liver diseases: a systematic review , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[11]  T. Uchida,et al.  Coffee consumption delays the hepatitis and suppresses the inflammation related gene expression in the Long-Evans Cinnamon rat. , 2014, Clinical nutrition.

[12]  F. Clavel-Chapelon,et al.  Adiposity, mediating biomarkers and risk of colon cancer in the European prospective investigation into cancer and nutrition study , 2014, International journal of cancer.

[13]  F. Hu,et al.  Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis , 2014, Diabetes Care.

[14]  C. la Vecchia,et al.  Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  M. Jiang,et al.  Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis , 2013, BMC Gastroenterology.

[16]  D. Rivelli,et al.  Coffee and Caffeine Protect against Liver Injury Induced by Thioacetamide in Male Wistar Rats , 2012, Basic & clinical pharmacology & toxicology.

[17]  N. Chavez-Tapia,et al.  High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. , 2012, Annals of hepatology.

[18]  H. Yatsuya,et al.  Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study , 2012, Nutrition & Diabetes.

[19]  U. Nöthlings,et al.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. , 2011, Journal of the National Cancer Institute.

[20]  R. Sinha,et al.  Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. , 2011, Gastroenterology.

[21]  Z. Bao,et al.  Coffee consumption and risk of cancers: a meta-analysis of cohort studies , 2011, BMC Cancer.

[22]  V. Wong,et al.  Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case–control study , 2010, Journal of Epidemiology & Community Health.

[23]  S. Kono,et al.  The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women , 2010, Clinical chemistry and laboratory medicine.

[24]  J. Tuomilehto,et al.  Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. , 2010, The American journal of clinical nutrition.

[25]  T. Moraes-santos,et al.  Effect of Coffee on Chemical Hepatocarcinogenesis in Rats , 2010, Nutrition and cancer.

[26]  William M. Lee,et al.  Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C , 2009, Hepatology.

[27]  K. Pfeiffer,et al.  Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. , 2008, Cancer research.

[28]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[29]  D. Jacobs,et al.  Is serum gamma-glutamyltransferase a biomarker of xenobiotics, which are conjugated by glutathione? , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Tae Hoon Lee,et al.  Serum aminotransferase activity and mortality risk in a United States community , 2008, Hepatology.

[31]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[32]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[33]  F. Hu,et al.  Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. , 2006, The American journal of clinical nutrition.

[34]  H. Boshuizen,et al.  Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[35]  Vincenzo Savarino,et al.  Liver enzyme alteration: a guide for clinicians , 2005, Canadian Medical Association Journal.

[36]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[37]  F. Clavel-Chapelon,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics , 2002, Public Health Nutrition.

[38]  Elio Riboli,et al.  The EPIC Project: Rationale and study design , 1997 .

[39]  H Boeing,et al.  Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. , 1997 .

[40]  H. Aberg,et al.  Oral contraceptives and back pain in women in a Swedish community. , 1997, International journal of epidemiology.

[41]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[42]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[43]  C. la Vecchia.  Coffee, liver enzymes, cirrhosis and liver cancer. , 2005, Journal of hepatology.

[44]  H. Boeing,et al.  Reproducibility and relative validity of energy and macronutrient intake of a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[45]  E Riboli,et al.  The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[46]  M. Ocké.  European prospective investigation into cancer and nutrition. Voedingsnavraag in de EPIC studie. , 1996 .

[47]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[48]  E. C. Fieller.  The Biological Standardization of Insulin , 1940 .